AKEBIA THERAPEUTICS, INC. Debt Securities, Available-for-sale
AKEBIA THERAPEUTICS, INC. (AKBA) had Debt Securities, Available-for-sale of $0 as of 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2022-03-01
- 2021-12-31: Debt Securities, Available-for-sale $0.00.
- 2021-09-30: Debt Securities, Available-for-sale $0.00.
- 2021-06-30: Debt Securities, Available-for-sale $0.00.
- 2021-03-31: Debt Securities, Available-for-sale $20.00M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2021-03-31 | $20.00M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $39.99M 10-K · filed 2022-03-01 |
| 2020-09-30 | $99.97M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $49.94M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 |
| 2019-12-31 | $245.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $22.73M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $49.55M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $105.30M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $217.00M 10-K · filed 2020-03-12 |
| 2018-09-30 | $227.71M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $238.60M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $234.86M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $247.64M 10-K · filed 2019-03-26 |
| 2017-09-30 | $240.11M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $195.82M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $164.56M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $73.01M 10-K · filed 2017-03-06 |
| 2016-09-30 | $95.49M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $142.47M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $173.59M 10-Q · filed 2016-05-05 |
| 2014-06-30 | $28.85M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $5.83M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $11.34M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |